Key Episode Timestamps
00:00:00 Introduction and Guest Introduction
00:00:52 Current State of Amyloid Therapeutics
00:03:41 Introduction of New Stabilizers and Silencers
00:06:05 Combination Therapy and Clinical Data
00:10:36 Choosing Therapy for Patients
00:16:40 Disease Progression and Clinical Trials
00:20:28 Pipeline and Future Therapies
00:23:51 Preventative Therapy and Asymptomatic Patients
00:27:19 Conclusion and Future Directions
This episode of Don’t Miss a Beat centers on the evolving treatment landscape for transthyretin amyloid cardiomyopathy (ATTR-CM) with special guest Ahmad Masri, MD. Hosts Muthiah Vaduganathan, MD, MPH, a cardiologist and codirector of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital, and Steve Greene, MD, an advanced heart failure specialist at Duke University School of Medicine, are joined by Masri, who serves as the director of the HCM and Amyloid Program at Oregon Health & Science University, to discuss the rapid therapeutic advances in ATTR-CM and the emerging questions shaping real-world clinical practice.
Masri reviews the progression from a previously untreatable disease to one now managed with three US Food and Drug Administration (FDA)-approved disease-modifying agents: tafamidis (VYNDAMAX), acoramidis (Attruby), and vutrisiran (AMVUTTRA).1,2,3
He highlights the tafamidis approval in 2019 as a landmark in the field, showing a substantial survival benefit in the ATTR-ACT trial, followed by similar results from acoramidis, which received approval in late 2024, in ATTRibute-CM.1,2
Vutrisiran, a TTR gene silencer approved by the FDA in March 2025, represents a mechanistically distinct approach validated in the HELIOS-B trial.3 Despite these advances, Masri notes that patients with late-stage disease derive limited symptomatic benefit and that residual risk remains high, even with treatment.
The conversation explores whether stabilizers and silencers can or should be combined, with Masri urging caution, citing the absence of clinical data demonstrating additive benefit and warning against assumptions of harmony without clinical evidence. Masri indicated ongoing trials, such as CARDIO-TTRansform, may offer clarity on this issue.4